Supriya Lifescience Share Price
Small Cap | Pharmaceuticals and health care | NSE: SUPRIYA | BSE: 543434
₹663.00 
-16.50 (-2.43 %)
Last Updated: 21 Feb 2025 04:01 PM
BEARISH
Overview
Open (₹) 687.95
High (₹) 687.95
Low (₹) 634.00
Prev. Close (₹) 679.50
Volume 34,161
VWAP (₹) 661.77
ROCE (%) 19.87
Industry P/E 43.99
TTM P/E 30.58
P/B Ratio 6.32
Market Cap (₹) Cr.5,149.69
Dividend Yield (%)0.12
EPS (₹) 14.80
ROE14.61%
Sales Growth (%) 23.74
Profit Growth (%)32.56
Day Range
687.95687.95
52 Week Range
304.05835.35
Historical Returns
Returns (6M)
16.89 %
Returns (1Y)
85.77 %
Returns (3Y)
60.16 %
Returns (5Y)
69.85 %
Returns (6M)
16.89 %
Returns (1Y)
85.77 %
Returns (3Y)
60.16 %
Returns (5Y)
69.85 %
SWOT Analysis
- Increasing Revenue every Quarter for the past 4 Quarters
- Strong long-term momentum: Price above long-term moving averages (EMA_200)
Technicals
Technical Rating
BEARISHRSI 50.01
MFI 45.03
ATR 51.62
Commodity Channel Index -77.62
ROC125 16.22
ROC21 -8.15
Williams %R -83.11
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 676.44 | 709.17 | 730.39 | 655.22 | 622.49 | 601.27 | 568.54 |
| Week Ago | 698.26 | 730.03 | 752.11 | 676.18 | 644.41 | 622.33 | 590.56 |
| Month Ago | 730.94 | 758.62 | 774.09 | 715.47 | 687.79 | 672.32 | 644.64 |
EMA & SMA
663.00
Current Price
Bullish Moving Averages
4
Bearish Moving Averages
16
5 Day 645.11
9 Day 668.47
10 Day 680.59
12 Day 703.43
14 Day 706.70
20 Day 689.84
26 Day 701.21
50 Day 711.86
100 Day 677.10
200 Day 563.66
Deals & Announcements
Bulk and Block Deals
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 28 Feb, 2024 | Shivani Satish Wagh | Acquisition | ₹ | 73,125 | BSE |
| 28 Feb, 2024 | Saloni Satish Wagh | Disposal | ₹ | 73,125 | BSE |
| 03 Apr, 2023 | Satish Waman Wagh | Acquisition | ₹190.2203846153846153846153846 | 13,000 | BSE |
| 31 Mar, 2023 | Satish Waman Wagh | Acquisition | ₹177.7857142857142857142857143 | 14,000 | BSE |
| 06 Mar, 2023 | Satish Waman Wagh | Acquisition | ₹203.691 | 2,000 | BSE |
| 06 Mar, 2023 | Satish Waman Wagh | Acquisition | ₹203.69075 | 8,000 | BSE |
| 02 Mar, 2023 | Satish Waman Wagh | Acquisition | ₹198.0575 | 2,000 | BSE |
| 02 Mar, 2023 | Satish Waman Wagh | Acquisition | ₹198.057625 | 8,000 | BSE |
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 28 May, 2024 | Rs.0.8000 per share(40%)Final Dividend | 20 Sept, 2024 | 01 Jan, 1970 |
| 26 May, 2023 | Rs.0.6000 per share(30%)Final Dividend | 15 Sept, 2023 | 01 Jan, 1970 |
| 20 May, 2022 | Rs.0.6000 per share(30%)Final Dividend | 01 Sept, 2022 | 01 Jan, 1970 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 18 Feb, 2025 | NSE India | Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 |
| 18 Feb, 2025 | BSE India | Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 |
| 10 Feb, 2025 | NSE India | Supriya Lifescience Limited has informed the Exchange about Schedule of meet |
| 10 Feb, 2025 | NSE India | Supriya Lifescience Limited has informed the Exchange about Schedule of meet |
| 10 Feb, 2025 | BSE India | Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 |
| 10 Feb, 2025 | BSE India | Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 |
| 01 Feb, 2025 | NSE India | Supriya Lifescience Limited has informed the Exchange regarding Cessation of Mr Kedar Karmarkar and Bhairav Chokshi as Non- Executive Independent Director of the company w.e.f. February 01, 2025. |
| 01 Feb, 2025 | BSE India | Intimation of retirement of Two Independent Directors upon completion of two consecutive terms in office |
| 31 Jan, 2025 | NSE India | Supriya Lifescience Limited has informed the Exchange about Transcript |
| 31 Jan, 2025 | BSE India | Transcript of the Earnings Call for the quarter and nine months ended December 31, 2024 |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results & Others | To consider other business matters. | 20 Jan, 2025 | 24 Jan, 2025 |
| Quarterly Results | -- | 22 Oct, 2024 | 28 Oct, 2024 |
| Quarterly Results | -- | 06 Aug, 2024 | 10 Aug, 2024 |
| Audited Results & Final Dividend | -- | 22 May, 2024 | 28 May, 2024 |
| Quarterly Results | -- | 31 Jan, 2024 | 07 Feb, 2024 |
| Quarterly Results | -- | 30 Oct, 2023 | 07 Nov, 2023 |
| Quarterly Results | -- | 28 Jul, 2023 | 03 Aug, 2023 |
| Audited Results & Final Dividend | -- | 22 May, 2023 | 26 May, 2023 |
| Quarterly Results | -- | 07 Feb, 2023 | 14 Feb, 2023 |
| Quarterly Results | -- | 03 Nov, 2022 | 10 Nov, 2022 |
Share Holding Pattern
| Owner Name | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sept, 2023 |
|---|
About Supriya Lifescience
Supriya Lifescience is a Public Limited Listed company incorporated on 26/03/2008 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L51900MH2008PLC180452 and registration number is 180452. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 570.37 Cr. and Equity Capital is Rs. 16.10 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
2008
Managing Director
-- --
NSE Symbol
SUPRIYA
Supriya Lifescience Management
| Name | Designation |
|---|---|
| Mr. Satish Waman Wagh | Exe.Chairman & W T D |
| Ms. Smita Satish Wagh | Whole Time Director |
| Ms. Saloni Satish Wagh | Whole Time Director |
| Ms. Shivani Satish Wagh | Whole Time Director |
| Mr. Balasahab Gulabrao Sawant | Whole Time Director |
| Mr. Kedar Shankar Karmarkar | Independent Director |
| Mr. Bhairav Manojbhai Chokshi | Independent Director |
| Mr. Dileep Kumar Jain | Independent Director |
| Mr. Dinesh Navnitlal Modi | Independent Director |
| Ms. Neelam Yashpal Arora | Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| SunPhrmInds | ₹4,46,576.22 | ₹1,643.75  ₹1,669.30(-1.53%) | ₹1,249.800 - ₹1,960.200 |
| Divis Labora | ₹1,56,123.40 | ₹5,757.05 ₹5,978.30(-3.70%) | ₹3,350.050 - ₹6,448.750 |
| Cipla | ₹1,21,675.13 | ₹1,475.75 ₹1,479.70(-0.27%) | ₹1,240.700 - ₹1,702.000 |
| ManKind Phar | ₹1,18,478.90 | ₹2,327.75 ₹2,348.45(-0.88%) | ₹1,910.100 - ₹3,050.000 |
| DrReddysLab | ₹1,15,939.04 | ₹1,151.80 ₹1,170.95(-1.64%) | ₹1,104.690 - ₹1,420.200 |
FAQs on Supriya Lifescience
What is the share price of Supriya Lifescience?
The share price of Supriya Lifescience on 21 Feb, 2025 is ₹ 663.00.
What is 52W high and 52W low share price of Supriya Lifescience?
The highest and lowest 52W share prices of Supriya Lifescience are ₹ 835.350 and ₹ 289.000
What is the market cap of Supriya Lifescience?
The market capitalization of Supriya Lifescience as of 21 Feb, 2025 is ₹ 5,149.69 Crores
What is the P/E ratio of Supriya Lifescience?
The current P/E ratio of Supriya Lifescience as of 21 Feb, 2025 is 43.99
What is the PB ratio of Supriya Lifescience?
The PB ratio of Supriya Lifescience as of 21 Feb, 2025 is 6.32
Top Gainers
948IHFL26I
IBHFL NCD186
₹845.00
₹705.00 (0.20%)
GREAVESCOT
Greaves
₹281.85
₹234.90 (0.20%)
ASHSI
Ashirwd Stl
₹45.66
₹38.05 (0.20%)
CAPRO
Caprola.Chem
₹62.40
₹52.00 (0.20%)
Top Losers
DHANBANK
Dhanalak.Bnk
₹32.19
₹35.97 (-0.11%)
08MPD
08MPD
₹8.66
₹9.62 (-0.10%)
BALTE
BalurghtTran
₹27.13
₹31.24 (-0.13%)
DARSHANORNA
Darshan Orna
₹4.57
₹5.07 (-0.10%)
Market Indices
Sensex
₹78,699.07
₹78,472.48 (0.00%)